GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Total Long-Term Liabilities

AGNPF (Algernon Pharmaceuticals) Total Long-Term Liabilities : $0.00 Mil (As of May. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Algernon Pharmaceuticals's Total Long-Term Liabilities for the quarter that ended in May. 2024 was $0.00 Mil.


Algernon Pharmaceuticals Total Long-Term Liabilities Historical Data

The historical data trend for Algernon Pharmaceuticals's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Total Long-Term Liabilities Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only - - - - -

Algernon Pharmaceuticals Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Algernon Pharmaceuticals Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Algernon Pharmaceuticals Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals Headlines

From GuruFocus

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

By Stock market mentor Stock market mentor 01-17-2023

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

By sperokesalga sperokesalga 03-01-2023